10-Q: SCWorx Corp. Reports Q1 2025 Results: Revenue Declines, Net Loss Widens Amid Strategic Shifts

SCWorx Corp. reports a decrease in revenue and an increased net loss for the first quarter of 2025, driven by contract expirations and increased operating expenses.

Summary

• SCWorx Corp. reported its financial results for the quarter ended March 31, 2025.
• Revenue decreased to $720,299 from $812,099 in the same period last year, primarily due to the expiration and non-renewal of customer contracts.
• The company's net loss widened to $476,303, compared to a net loss of $178,659 in the first quarter of 2024.
• Operating expenses increased to $470,860, driven by higher legal and professional fees, and increased spending on marketing and sales efforts.
• The company issued 191,250 shares of common stock valued at $148,410 as partial fulfillment of a legal settlement.
• The company issued 54,980 shares of common stock for the conversion of $40,000 in principal and $7,283 in accrued interest on convertible notes.
• The company issued warrants to purchase 7,256,364 shares of common stock at exercise prices ranging from $1.25 to $1.65 per share in conjunction with a convertible note issuance.
• Management has concluded that conditions exist that raise substantial doubt about the company's ability to continue as a going concern.
• The company received a notification from Nasdaq that it no longer meets the minimum bid price requirement and has until October 7, 2025, to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to declining revenue, increasing losses, a going concern warning, and Nasdaq non-compliance. While there are some positive aspects like increased cash, the overall outlook is concerning.

Positives

• Cash increased significantly to $1,072,416 from $106,654 at the end of 2024.
• Accounts receivable decreased from $372,716 to $175,233.
• The company is actively working to address the Nasdaq minimum bid price deficiency.

Negatives

• Revenue decreased by approximately 11.3% compared to the same quarter last year.
• The net loss increased significantly, indicating worsening financial performance.
• Operating expenses increased, driven by higher legal and professional fees.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is not in compliance with Nasdaq's minimum bid price requirement.

Risks

• The company's ability to continue as a going concern is uncertain.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• The company faces risks associated with litigation proceedings.
• The company's reliance on debt financing and the need to raise additional capital pose financial risks.
• The company's business is subject to risks related to evolving industry standards and market conditions.

Future Outlook

The company expects operating expenses to remain relatively flat during the rest of 2025, with the exception of marketing and advertising. Management has concluded that conditions exist that raise substantial doubt about the company's ability to continue as a going concern.

Management Comments

• Management conducted an evaluation of the effectiveness of our disclosure controls and procedures.
• Based upon this evaluation, our President and Chief Financial Officer have concluded that, due to deficiencies in the design of internal controls and lack of segregation of duties, our Disclosure Controls were not effective as of March 31, 2025.

Industry Context

SCWorx operates in the health information technology sector, providing data content and services to healthcare providers. The company's performance is affected by factors such as the adoption of its solutions by hospitals and health systems, competition from other vendors, and changes in healthcare regulations and industry standards.

Comparison to Industry Standards

• It is difficult to compare SCWorx's results directly to industry standards without specific data on comparable companies and projects.
• However, the decline in revenue and increased net loss suggest that SCWorx is underperforming compared to some of its peers.
• Companies like Cerner (now Oracle Health) and Allscripts (now Veradigm) are larger players in the healthcare IT space, but they offer a broader range of services.
• Smaller, more specialized companies like SCWorx may face challenges in competing with these larger firms.
• The going concern warning is a significant concern, as it indicates that SCWorx may be facing financial difficulties that could impact its ability to operate.

Legal Proceedings

• The company is involved in a legal proceeding with Core IR, which has resulted in a settlement agreement involving the issuance of common stock.

Related Party Transactions

• The company had a payable due to an officer in the amount of $149,838 for contract work performed prior to becoming an officer.
• The company had a balance of $67,622 included in shareholder advance on the Companys unaudited condensed consolidated balance sheets as of March 31, 2025 and December 31, 2024.

Stakeholder Impact

• Shareholders face the risk of further stock dilution due to the issuance of shares for legal settlements and note conversions.
• Employees may be concerned about the company's financial stability and its ability to continue operations.
• Customers may be concerned about the company's ability to provide ongoing services and support.
• Creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company must address the Nasdaq minimum bid price deficiency by October 7, 2025.
• The company needs to improve its financial performance to alleviate concerns about its ability to continue as a going concern.
• The company needs to manage its legal proceedings and contract commitments.

Key Dates

Keywords

financial results, revenue, net loss, SCWorx, healthcare, data, going concern, Nasdaq, convertible notes, warrants